Статья
Использование амбулаторных методов измерения артериального давления для оценки эффективности антигипертензивной терапии
Контроль эффективности антигипертензивной терапии на основании только результатов традиционных клинических измерений артериального давления (АД) связан с очевидными ограничениями. В связи с этим в последнее время все больше внимание привлекает самоконтроль АД(СКАД). Достоинствами данного метода являются доступность, возможность учесть спонтанные колебания АД в течение длительного времени, прогностическая значимость получаемых результатов. К ограничениям СКАД относится невозможность получения информации о многих характеристиках суточного профиля АД. В частности, оценка равномерности антигипертензивного эффекта препаратов является прерогативой суточного мониторирования АД (СМАД). Актуальными задачами дальнейших исследований представляются разработка оптимальных режимов СКАД, а также изучение сравнительной информативности СМАД и СКАД в контролируемых клинико-фармакологических исследованиях.
1. Manchia G. Clinical use of ambulatory blood pressure. Am J Hyper 1989; 2: 505-45.
2. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-53.
3. Pickering T, James GD, Mallion JM, et al. Task Force V. Withecoat hypertension. Blood Press Monit 1999; 4: 333-41.
4. Schnall PL, Pickering TG, Karasek RA. The relationship of job characteristics, social support and psychological traits to ambulatory blood pressure-initial of a case-control study. Circulation 1987; 76(4): 396-401.
5. Staessen JA, Fagard R, Lutgarde T, et al. Randomized doubleblind comparison of placebo and active treatment for older people with isolated systolic hypertension (Syst-Eur Trial). Lancet 1997; 350: 757-84.
6. Шакирова Г.О., Ощепкова Е.В., Рогоза А.Н. и др. Баро-рецепторный контроль и суточная вариабельность АД у больных с «мягкой» артериальной гипертонией и гемодинамически незначимым атеросклеротическим поражений сонных артерий. Кардиология 1992; 11(2): 15-8.
7. Asmar R, Zanchetti A. Guidelines for the use of self blood pressure monitoring : a summary report of the first international consensus conference. J Hypertens 2000; 18: 493-508.
8. Rhombery F, Bachman D, Bachtold H, Muller P. Initial experience with the calcium antagonist tiapamil in the treatment of hypertension. Sweiz Med Worchenschr 1983; 113: 1845-6.
9. Schu D, De Gori D. Antihypertensive effect of tiapamil, a calcium antagonist. Double-blind placebo crossover study. Cardiology 1982; 69(Suppl 1): 99-104.
10. Caruana M, HL-Khawaja I, Prince H, Raftery EB. Effects of tiapamil, a new calcium channel blocker, on ambulatory intraarterial blood pressure and exercise induced changes of blood pressure. J Cardiovasc Pharmacol 1983; 8: 1074-7.
11. Lacourciere Y, Carrier M, Toal CB. Efficacy and tolerability of tiapamil in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1989; 14: 166-70.
12. Staessen J. Ambulatory blood pressure in clinical trials. Blood Press Monit 2000; 5: 39-41.
13. Kario K. Clinician’s manual on early morning rick management in hypertension. Current Medicine Group LDT; 2005: 68 p.
14. Mallion JM, Genes N, Vaur L, et al. Blood pressure levels, risk factors and antihypertensive treatments: lessons from the SHEAF study. J Hum Hypertens 2001; 15(12): 831-2.
15. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291(11): 1342-9.
16. Kario K, Eguchi K, Umeda Y, et al. Morning surge in blood pressure as a predictor of silend and cerebrovascular disease in elderly hypertensives. Response. Circulation 2003; 108: 72e-3.
17. Vetter W, Hess L, Brignoli R. Influence of self-measurement of blood pressure on the responder rate in hypertensive patients treated with losartan: results of the SVATCH Study. Standard vs Automatic Treatment Control of COSAAR in Hypertension. J Hum Hypertens 2000; 14(4): 235-41.
18. Pickering TG, Hall JE, Appel LJ, et al. Recommendation for Blood Pressure Measurement in Humans and Experimental Animals. Part 1: Blood Pressure Measurement in Humans. A Statement for Professionals From the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111: 697-716.
19. Yarows SA, Julius S, Pickering TG. Home blood pressure monitoring. Arch Intern Med 2000; 160: 1251-7.
20. Brook RD. Home blood pressure: accuracy is independent of monitoring schedules. Am J Hypertens 2000; 13: 625-31.
21. Цагареишвили Е.В., Ощепкова Е.В., Зелвиян П.А., Рогоза А.Н. Возможности метода самоконтроля артериального давления оценки эффективности гипотензивной терапии индапамидом и повышении приверженности к лечению у больных гипертонической болезнью в амбулаторных условиях. Кардиология 2004; 8: 62-6.
22. Stergiou GS, Zourbaki AS, Skeva II, Mountokalakis TD. White coat effect detected using self-monitoring of blood pressure at home: comparison with ambulatory blood pressure. Am J Hypertens 1998; 11: 820-7.
23. Den Hong E, Celis H, Vandenhoven G, et al; THOP investigators. Determinants of white-coat syndrome assessed by ambulatory blood pressure or self-measured home blood pressure. Blood Press Monit 2003; 8(1): 37-40.
24. Kjeldsen SE, Hedner T, Syvertsen JO, Lund-Johansson L; NORDIL Group. Nordic Diltiazem. Comparison of home and office blood pressure in treated hypertensive in the Nordic Diltiazem (NORDIL) Study. Blood Press 2002; 11(6): 371-6.
25. Stergiou GS, Thomopoulou GC, Skeva II, Mountokalakis TD. Home blood pressure normalcy: the Didima study. Am J Hypertens 2000; 13: 678-85.
26. Kjeldsen SE, Hedner T, Jamerson K, et al. Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension 1998; 31: 1014-20.
27. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patient with hypertension principal result of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62.
28. Reims H, Fossum E, Kyeldsen S, Julius S. Home blood pressure monitoring. Current knowledge and directions for future research. Blood Pressure 2001; 10: 271-87.
29. Parati G, Ulian L, Sampieri L, et al. Attenuation of the ‘whitecoat’ effect by antihypertensive treatment and regression of target organ damage. Hypertension 2000; 35: 614-20.
30. Imai Y, Ohkubo T, Hozawa A, et al. Usefulness of home blood pressure measurements in assessing the effect of treatment in a single-blind placebo-controlled open trial. J Hypertens 2001; 19: 179-85.
31. Ragot S, Genes N, Vaur L, Herpin D. Comparison of three pressure measurement methods for the evaluation of two antihypertensive drugs: feasibility, agreement and reproducibility of blood pressure response. Am J Hypertens 2000; 13(6 Pt 1): 632-9.
32. Campo C, Fernandez G, Gonzalez-Esteban J, et al. Comparative study of home and office blood pressure in hypertensive patients treated with enalapril/HCTZ 20/6 mg: the ESPADA study. Blood Press 2000; 9: 355-62.
33. James GD, Pickering TG, Harshfield GA, et al. The reproducibility of average ambulatory, home and clinic pressures. Hypertension 1988; 11: 545-9.
34. Stergiou GS, Baibas NM, Gantzarou AP, et al. Reproducibility of home, ambulatory and clinic blood pressure: implications for the design of trials for the assessment of antihypertensive drug efficacy. Am J Hypertens 2001; 14: 38A.
35. Chatellier G, Dutrey-Dupagne C, Vaur L, et al. Home self blood pressure measurement in general practice. The SMART study. Am J Hypertens 1996; 9(7): 644-52.
36. Ragot S, Ezzaher A, Meunier A, et al. Comparison of effect of telmisartan vs perindopril using self blood pressure measurement: EVEREST Study. J Hum Hypertens 2002; 16(12): 865-73.
37. Mancia G, Korlipara K, van Rossum P, et al. An ambulatory blood pressure monitoring study of the comparative efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135-42.
38. Menard J, Chatellieer G, Day M, Vaur L. Self-measurement of blood pressure at home to evaluate drug effects by the trough: peak ratio. J Hypertens 1994; 12(Suppl 8): S21.
39. Nishimura T, Hashimoto J, Ohkubo T, et al. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor, losartan, candesartan, valsartan and telmisartan, in patiens with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens 2005; 27(6): 477-89.
40. Kario K, Shimada K, Pickering TG. Clinical implication of morning blood pressure surge in hypertension. J Cardiovasc Pharmacol 2003; 42(Suppl): S87-91.
41. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early moning period. Am J Hypertens 2004; 17: 347-53.
42. Lacourciere Y, Krzesinski JM, White WB, et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9: 203-10.
43. Lacourciere Y, Lenis J, Orchard R, et al; on behalf the Canadian Telmisartan Study Group. A comparision of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998; 3: 295-302.
44. Lacourciere Y, Neutel J, Koval SE, et al. A prospective, randomized investigation of the safety and efficacy of telmisartan vs ramipril in mild-to-moderate hypertensives using ambulatory blood pressure monitoring. 9th Annual Meeting of the European Council for Blood Pressure and Cardiovascular Research (ECCR), Nice. 1-3 October 2004. Hypertension 2004; 44: 576.
45. Willliams B, Grosse P, Lowe L, et al. Superior BP reduction in the last 6 h of the dosing interval with once-daily telmisartan vs ramipril. 9th Annual Meeting of the European Council for Blood Pressure and Cardiovascular Research (ECCR), Nice. 1-3 October 2004. Hypertension 2004; 44: 576.
46. Chonan K, Hashimoto J, Ohkubo T, et al. Insufficient duration of action of antihypertensive drugs mediates high blood pressure in the moning in hypertensive population: the Ohasama study. Clin E xp Hypertens 2002; 24(4): 261-75.
47. Staessen JA, Den Hong E, Celis H, et al. Treatment of Hypertension Based on Home or Office Blood Pressure (THOP) Trial Investigators. Antihypertensive treatment based on blood pressure measurement at home or in the physician’s office: randomized controlled trial. JAMA 2004; 219(8): 955-64.
48. Staessen JA, Byttebier G, Buntinx F, et al. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. JAMA 1997; 278: 1063-72.
49. Ikeda T, Yamamoto K, Okado J, et al. Morning rise in blood pressure associates with hypertensive cardiovascular complications. J Hypertens 2002; 20(Suppl 4): S150.
50. Luders S, Rothemeyer M, Zuchner C, et al. Ambulatory blood pressure monitoring (ABPM) vs. Office blood pressure measurement (OM) – A prospective longterm study on the benefits during antihypertensive treatment. J Hypertens 1998; 16(Suppl. 2): S215.
51. Aoki Y, Asayama K, Ohkubo T, et al. HOMER-BP Study Group. Progress report on the HOMED-BP Study: hypertension objective treatment based on measurement by electrical devices of blood pressure study. Clin Exp Hypertens 2004; 26(2): 119-27.
52. Saito S, Asayama K, Ohkubo T, et al. HOMER-BP Study Group. The second progress report on the Hypertension Objective treatment based on Measurement by Electrical Devices of Blood Pressure (HOMER-BP) study. Blood Press Monit 2004; 9(5): 243-7.
53. Fitzerald DJ, O’Malley K, O’Brien ET. Reproducibility of ambulatory blood pressure recording. New York 1983; 71-4.
54. Горбунов В.М., Оганов Р.Г., Деев А.Д. Сравнительная информативность различных способов анализа результатов суточного мониторирования артериального давления в оценке эффективности антигипертензивной терапии. Кардиоваск тер профил 2003; 2(1): 17-25.
55. Горбунов В.М. Проблемы оценки эффективности антигипертензивной терапии с помощью суточного мониторирования артериального давления. Кардиология 2003; 10: 105-12.
56. Кобалава Ж.Д., Котовская Ю.В., Хирманов В.Н. Артериальное давление в исследовательской клинической практике. Москва «Реафарм» 2004; 198-9.
57. Parati G, Omboni S, Rizzoni D, et al. The smoothness index: a new, reproducible and clinically relevant measure of homogenate of the blood pressure reduction with treatment for hypertension. J Hypertens 1998; 16: 1685-91.
58. Рогоза А.Н., Никольский В.П., Ощепкова Е.В. и др. Под ред. Арабидзе Г.Г. и Атькова О.Ю. Суточное мониторирование артериального давления при гипертонии. Методические вопросы 1997; 52 с.
59. Rose M, MacMahon FG. Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens 1990; 3: 151-5.
60. Mancia G, Casadei R, Mutti E, et al. Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment. Am J Med 1989; 87(Suppl 6b): S64-9.
61. Lipicky RJ. Trough: peak ratio: the rationale behind the United States Food and Drug administration recommendations. J Hypertens 1994; 12(Suppl 8): S17-9.
62. Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment – induced Regression of left ventricular hypertrophy. Circulation 1997; 95: 1464-70.
63. Rizzoni D, Muiesan ML, Salvetti M, et al. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J Hypertens 2001; 19: 703-11.
64. Горбунов В.М. Рациональное использование 24-часового мониторирования артериального давления для оценки эффективности антигипертензивной терапии. Автореф дисс докт мед наук 2003; 34-5.
65. Coca A, Calvo C, Sorbino J, et al. Once-daily fixed-combination irbesartan 300 mg/hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther 2003; 25(11): 2849-64.
66. Palatini P, Mugellini A, Spagnuolo V, et al. Investigators Group. Comprarison of the effeats on 24-h ambulatory blood pressure of valsartan anad amlodipine? Alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). Blood Press Monit 2004; 9(2): 91-7.
67. Parati G, Ulian L, Santucciu C, Mancia G. Reproducibility of blood pressure measurements. Blood Press Monit 1996; 1: 205-9.
68. Mancia G, Parati G. Importance of smooth and sustained blood pressure control in preventing cardiovascular morbidity and mortality. Blood Press (Suppl.) 2001; 3: 26-32.
69. Горбунов В.М. Значение самостоятельного измерения артериального давления больными с артериальной гипертонией. Кардиология 2002; 1: 58-66.
70. Горбунов В.М. Значения исследования различных видов вариабельности артериального давления у больных с артериальной гипертонией. Кардиология 1997; 1: 66-9.
71. Горбунов В.М., Метелица В.И., Дуда С.Г. и др. Степень ночного снижения артериального давления: воспроизводимость и эффект трех -блокаторов. Кардиология 1999; 4: 21-5.
72. Palatini P. Importance of various methods of blood pressure measurement in clinical trials. Curr Hypertens Rep 2000; 2(4): 362-9.
73. Stergiou GS, Efstathiou SP, Skeva II, et al. Assessment of drug effects on blood pressure and pulse pressure using clinic, home and ambulatory measurements. J Hum Hypertens 2002; 16(10): 729-35.
74. Omboni S, Parati G, Zanchetti A, Mancia G. Calculation of the trough: peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens 1995; 13: 1105-12.
75. Mancia G, Di Rienzo M, Parati G. Ambulatory blood pressure monitoring; use in hypertension research and clinical practice. Hypertension 1993; 21:510-24.
76. Imai Y, Hozawa A, Ohkubo T, et al. Predictive values of automated blood pressure measurement: what can we learn from the Japanese population - the Ohasama study. Blood Press Monit 2001; 6(6): 335-9.
77. Mancia G, Zanchetti A, Agabiti-Rosei E, et al. For the Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation (SAMPLE) Study Group. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatmentinduced regression of left ventricular hypertrophy. Circulation 1997; 95: 1464-70.
78. Parati G. Blood pressure variability, target organ damage and antihypertensive treatment. J Hypertens 2003; 21: 1827-30.
79. Verdecchia P, Borgioni C, Ciucci A, et al. Prognostic significance of blood pressure variability in essential hypertension. Blood Press Monit 1996; 1: 3-11.
80. Kikuya M, Hozawa A, Ohokubo T, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama Study. Hypertension 2000; 36: 901-6.
81. Sega R, Corrao G, Bombelli M, et al. Blood pressure variability and organ damang in a general population: results from the PAMELA study. Hypertension 2002; 39: 710-4.